Doctors hail Moderna and Merck melanoma vaccine results as a major advance
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
In a phase 3 trial of roughly 1,100 post-surgery melanoma patients, Moderna and Merck’s personalized vaccine intismeran autogene plus Keytruda cut the risk of recurrence or death by 42% and the risk of distant spread or death by 38% versus Keytruda alone. Six specialists called the results clinically meaningful.
Continue in the app — vote & join in ➔Source: CNBC Top News · via ahirlevel.hu